Cargando…

Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma

Bortezomib/thalidomide/dexamethasone (VTD) induction therapy followed by autologous stem cell transplantation (ASCT) is one of the standard therapies for newly diagnosed multiple myeloma (NDMM). However, the appropriate depth of response to induction therapy and timing of upfront ASCT are still deba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yoo Jin, Moon, Joon Ho, Sohn, Sang Kyun, Kim, Seok Jin, Jung, Sung-Hoon, Lee, Je-Jung, Jo, Jae-Cheol, Shin, Ho-Jin, Lee, Won Sik, Lee, Ji Hyun, Bae, Sung Hwa, Kim, Min Kyoung, Lee, Ho Sup, Kim, Kihyun, Min, Chang-Ki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763096/ https://www.ncbi.nlm.nih.gov/pubmed/31358918 http://dx.doi.org/10.1038/s41409-019-0629-7

Ejemplares similares

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
por: Fouquet, Guillemette, et al.
Publicado: (2014)

P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN
por: Del Fabro, V., et al.
Publicado: (2023)

Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching
por: Moreau, Philippe, et al.
Publicado: (2020)

Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible
por: Sonneveld, Pieter, et al.
Publicado: (2020)

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
por: Terragna, Carolina, et al.
Publicado: (2015)

Short-course bortezomib-based retreatment for patients with multiple myeloma who had received bortezomib-thalidomide-dexamethasone (VTD) as an initial therapy: A single-center case series
por: MAO, JINGJUE, et al.
Publicado: (2014)

The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
por: Du, Jeng-Shiun, et al.
Publicado: (2022)

Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study
por: Byun, Ja Min, et al.
Publicado: (2023)

VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience
por: Ghandili, Susanne, et al.
Publicado: (2022)

Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosis
por: Srkalovic, Gordan, et al.
Publicado: (2005)

Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study
por: Jung, Jongheon, et al.
Publicado: (2023)

Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD
por: Chim, Chor Sang, et al.
Publicado: (2012)

The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
por: Kim, Cheolsu, et al.
Publicado: (2015)

Psychometric Characteristics of Different Versions of Vocal Tract Discomfort (VTD) Scale: A Systematic Review
por: Aghaei, Fateme, et al.
Publicado: (2022)

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma
por: Nadiminti, Kalyan, et al.
Publicado: (2017)

Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient
por: Kang, Wonseok, et al.
Publicado: (2010)

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
por: Wu, Shenghao, et al.
Publicado: (2015)

Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and (18)F-FDG PET/CT
por: Cho, Hee Jeong, et al.
Publicado: (2021)

Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP‐164 study)
por: Lee, Ho Sup, et al.
Publicado: (2020)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
por: Rosiñol, Laura, et al.
Publicado: (2023)

Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study
por: Kwon, Jihyun, et al.
Publicado: (2016)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

Effect of Autologous Stem Cell Transplantation Combined with Modified VTD Regimen on Elderly Patients with Multiple Myeloma and Its Influence on miRNA Cytokines
por: Bai, Zhaoliang, et al.
Publicado: (2022)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016)

Higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma
por: Xu, Peipei, et al.
Publicado: (2019)

Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
por: Cho, Hee-Jeong, et al.
Publicado: (2018)

Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation
por: Lee, Ho Sup, et al.
Publicado: (2013)

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
por: Crusoe, Edvan De Queiroz, et al.
Publicado: (2020)

High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group
por: Hus, Iwona, et al.
Publicado: (2019)

Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
por: Suzuki, Kenshi, et al.
Publicado: (2023)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma
por: Kim, Sung Min, et al.
Publicado: (2014)

P976: REAL-WORLD OUTCOMES OF PATIENTS WITH PENTA-EXPOSED MULTIPLE MYELOMA WHO WERE TREATED WITH SELINEXOR AND DEXAMETHASONE: KOREAN MULTICENTER RETROSPECTIVE ANALYSIS
por: Ho Yi, Jun, et al.
Publicado: (2023)

Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen
por: Kim, Su-In, et al.
Publicado: (2022)

P20 LENALIDOMIDE MAINTENANCE AFTER VTD INDUCTION AND AUTOLOGOUS STEM CELL TRANSPLANTATION: PRELIMINARY RESULTS OF A REAL-LIFE STUDY INCLUDING 389 PATIENTS
por: Barilà, G., et al.
Publicado: (2023)

A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma
por: Chim, C. S., et al.
Publicado: (2010)

Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study)
por: Song, Ga-Young, et al.
Publicado: (2022)

Continuous treatment with lenalidomide and low‐dose dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial
por: Lu, Jin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tvki1f5dmjivri00i01ktv5pkt